Telaprevir: Additional Phase III data

A subgroup analysis of African Americans (n=73), Hispanics (n=54) and patients with advanced liver fibrosis or cirrhosis (n=149) in the open-label, international Phase III ILLUMINATE trial in 540 treatment-naïve patients with HCV genotype 1 infection showed that 60%, 67% and 63% of patients, respectively, achieved an SVR with telaprevir-based therapy. Data were presented at the American Association for the Study of Liver Diseases meeting in Boston. ...